Korean Circ J.  2021 Oct;51(10):837-850. 10.4070/kcj.2021.0098.

Late Coronary Aneurysm Formation after Kawasaki Disease: a Review of Mechanistic and Clinical Aspects

• Yalta K
• Yalta T
• Yetkin E
• Ozturk C

• KMID: 2520691
• DOI: http://doi.org/10.4070/kcj.2021.0098

Abstract

In patients with Kawasaki disease (KD), evolution of coronary artery aneurysms (CAAs) generally emerges within the first few weeks after disease onset. However, CAA formation in these patients might occasionally arise as a late-onset phenomenon after a long latent period. Characteristically, late CAAs manifest as new-onset vascular pathologies or expansion of long-stable CAAs on coronary imaging modalities, and might have diverse mechanistic and clinical implications. Accordingly, the present paper aims to focus on late CAA formation and its implications in the setting of KD.

Keyword

Kawasaki disease; Coronary artery; Aneurysm

Figure

• 

  Figure 1 Potential mechanisms of late CAA formation in the setting of KD.CAA = coronary artery aneurysm; KD = Kawasaki disease.*Generally presenting with mild and transient dilatation of coronary arteries.1)8)9)

Reference

1. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017; 135:e927–e999. PMID: 28356445.

2. Pacheco DA, Miller CR, Boor PJ, Mambo NC. Incomplete Kawasaki disease with development of fatal coronary artery thrombosis in a 13-year-old male. Cardiovasc Pathol. 2019; 42:54–58. PMID: 31306942.

3. Pucci A, Martino S, Celeste A, et al. Angiogenesis, tumor necrosis factor-alpha and procoagulant factors in coronary artery giant aneurysm of a fatal infantile Kawasaki disease. Cardiovasc Pathol. 2008; 17:186–189. PMID: 18402791.

4. Yan ZT, Zou JW. Triptolide as an alternative to IVIG therapy for Kawasaki disease in a mouse model. Balkan Med J. 2013; 30:225–228. PMID: 25207104.

5. Lee CH, Kim U. Coronary artery aneurysm in Kawasaki disease: from multimodality imaging. Coron Artery Dis. 2020; 31:193–194. PMID: 31821196.

6. Kitamura S. The role of coronary bypass operation on children with Kawasaki disease. Coron Artery Dis. 2002; 13:437–447. PMID: 12544719.

7. Hedgire S, Pulli B, Lahoud-Rahme M, Beroukhim RS, Rosales AM, Ghoshhajra B. Kawasaki disease with giant coronary artery aneurysms. Coron Artery Dis. 2017; 28:177–179. PMID: 27755008.

8. Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J Am Coll Cardiol. 2016; 67:1738–1749. PMID: 27056781.

9. Yalta K, Gurdogan M, Taylan G. Late coronary aneurysm formation in Kawasaki disease: a subtle phenomenon with potential implications [Internet]. London: Heart;2019. cited 2019 December 20. Available from: https://heart.bmj.com.

10. Tsuda E, Kamiya T, Ono Y, Kimura K, Echigo S. Dilated coronary arterial lesions in the late period after Kawasaki disease. Heart. 2005; 91:177–182. PMID: 15657227.

11. Toyono M, Shimada S, Aoki-Okazaki M, et al. Expanding coronary aneurysm in the late phase of Kawasaki disease. Pediatr Int. 2012; 54:155–158. PMID: 22335330.

12. Ozawa J, Suzuki H, Hasegawa S, et al. Two cases of new coronary aneurysms that developed in the late period after Kawasaki disease. Pediatr Cardiol. 2013; 34:1992–1995. PMID: 23052675.

13. Tomita H, Fuse S, Chiba S. Images in cardiology. Delayed appearance of coronary aneurysms in Kawasaki disease. Heart. 1998; 80:425. PMID: 9930035.

14. Yalta K, Yilmaz MB, Yalta T, Palabiyik O, Taylan G, Zorkun C. Late versus early myocardial remodeling after acute myocardial infarction: a comparative review on mechanistic insights and clinical implications. J Cardiovasc Pharmacol Ther. 2020; 25:15–26. PMID: 31416353.

15. Muzik O, Paridon SM, Singh TP, Morrow WR, Dayanikli F, Di Carli MF. Quantification of myocardial blood flow and flow reserve in children with a history of Kawasaki disease and normal coronary arteries using positron emission tomography. J Am Coll Cardiol. 1996; 28:757–762. PMID: 8772768.

16. Ozturk S, Yetkin E, Waltenberger J. Molecular and cellular insights into the pathogenesis of coronary artery ectasia. Cardiovasc Pathol. 2018; 35:37–47. PMID: 29772448.

17. Huang QJ, Liu J, Chen MH, Li JJ. Relation of diabetes to coronary artery ectasia: A meta-analysis study. Anadolu Kardiyol Derg. 2014; 14:322–327. PMID: 24818774.

18. Androulakis AE, Andrikopoulos GK, Kartalis AN, et al. Relation of coronary artery ectasia to diabetes mellitus. Am J Cardiol. 2004; 93:1165–1167. PMID: 15110214.

19. Pinar Bermúdez E, López Palop R, Lozano Martínez-Luengas I, et al. Coronary ectasia: prevalence, and clinical and angiographic characteristics. Rev Esp Cardiol. 2003; 56:473–479. PMID: 12737785.

20. Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes. 2002; 51:3063–3068. PMID: 12351448.

21. Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. Pediatrics. 2005; 116:989–995. PMID: 16199713.

22. Zhao CN, Du ZD, Gao LL. Corticosteroid therapy might be associated with the development of coronary aneurysm in children with Kawasaki disease. Chin Med J (Engl). 2016; 129:922–928. PMID: 27064036.

23. Suzuki A, Miyagawa-Tomita S, Nakazawa M, Yutani C. Remodeling of coronary artery lesions due to Kawasaki disease: comparison of arteriographic and immunohistochemical findings. Jpn Heart J. 2000; 41:245–256. PMID: 10987345.

24. Iskandar Z, Mordi I, Lang CC, Huang JT, Choy AM. Biomarkers of aortopathy in Marfan syndrome. Cardiol Rev. 2020; 28:92–97. PMID: 31985522.

25. Radke RM, Baumgartner H. Diagnosis and treatment of Marfan syndrome: an update. Heart. 2014; 100:1382–1391. PMID: 24777611.

26. Kobayashi T, Sone K, Shinohara M, Kosuda T, Kobayashi T. Images in cardiovascular medicine. Giant coronary aneurysm of Kawasaki disease developing during postacute phase. Circulation. 1998; 98:92–93. PMID: 9665066.

27. Mawatari T, Koshino T, Morishita K, Komatsu K, Abe T. Successful surgical treatment of giant coronary artery aneurysm with fistula. Ann Thorac Surg. 2000; 70:1394–1397. PMID: 11081907.

28. Gersony WM. Diagnosis and management of Kawasaki disease. JAMA. 1991; 265:2699–2703. PMID: 2023352.

29. Morita H, Ozawa H, Yamazaki S, et al. A case of giant coronary artery aneurysm with fistulous connection to the pulmonary artery: a case report and review of the literature. Intern Med. 2012; 51:1361–1366. PMID: 22687842.

30. Li D, Wu Q, Sun L, et al. Surgical treatment of giant coronary artery aneurysm. J Thorac Cardiovasc Surg. 2005; 130:817–821. PMID: 16153934.

31. Yasukawa K, Sonobe T, Yamamoto W, et al. The evolution of newly developed coronary aneurysm in the chronic stage of Kawasaki disease and the usefulness of MRCA. Prog Med. 2003; 23:1778–1783.

32. Nakada T, Yonesaka S, Sunagawa Y, et al. Coronary arterial calcification in Kawasaki disease. Acta Paediatr Jpn. 1991; 33:443–449. PMID: 1792902.

33. Ferrara G, Giani T, Caparello MC, Farella C, Gamalero L, Cimaz R. Anakinra for treatment-resistant Kawasaki disease: evidence from a literature review. Paediatr Drugs. 2020; 22:645–652. PMID: 32885390.

34. Guillaume MP, Reumaux H, Dubos F. Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm. Cardiol Young. 2018; 28:739–742. PMID: 29455693.

35. Gorelik M, Lee Y, Abe M, et al. IL-1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis. Clin Exp Immunol. 2019; 198:101–110. PMID: 31099056.

36. Matsuoka R, Furuno K, Nanishi E, et al. Delayed development of coronary artery aneurysm in patients with Kawasaki disease who were clinically responsive to immunoglobulin. J Pediatr. 2020; 227:224–230.e3. PMID: 32810506.

37. Inoue N, Takai S, Jin D, et al. Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease. Clin Chim Acta. 2010; 411:267–269. PMID: 19945447.

38. Brogan P, Burns JC, Cornish J, et al. Lifetime cardiovascular management of patients with previous Kawasaki disease. Heart. 2020; 106:411–420. PMID: 31843876.

39. Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation. 2020; 142:40–48. PMID: 32436455.

40. Pham V, Hemptinne Q, Grinda JM, Duboc D, Varenne O, Picard F. Giant coronary aneurysms, from diagnosis to treatment: a literature review. Arch Cardiovasc Dis. 2020; 113:59–69. PMID: 31866173.

41. De Hous N, Haine S, Oortman R, Laga S. Alternative approach for the surgical treatment of left main coronary artery aneurysm. Ann Thorac Surg. 2019; 108:e91–e93. PMID: 30684476.

42. Kawsara A, Núñez Gil IJ, Alqahtani F, Moreland J, Rihal CS, Alkhouli M. Management of coronary artery aneurysms. JACC Cardiovasc Interv. 2018; 11:1211–1223. PMID: 29976357.